{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.3724","statisticalMethod":"Stratified Log-rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.24","upperLimit":"5.36","value":"4.47"},{"groupId":"OG001","lowerLimit":"4.04","upperLimit":"5.36","value":"4.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"220"}],"units":"Participants"}],"description":"PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Triplet Arm"},{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG001","title":"Phase 3: Doublet Arm"}],"paramType":"MEDIAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants.","reportingStatus":"POSTED","timeFrame":"From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)","title":"(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator","type":"SECONDARY","unitOfMeasure":"Months"}